Abstract Vessel formation is of critical importance for organ function in the normal and diseased state. In particular, the labeling and quantitation of small vessels prove to be technically challenging using current approaches. We have, therefore, established a transgenic embryonic stem (ES) cell line and a transgenic mouse model where the vascular endothelial growth factor receptor VEGFR-1 (flt-1) promoter drives the expression of the live reporter eGFP. Fluorescence microscopy and immunostainings revealed endothelial-specific eGFP labeling of vascular networks. The expression pattern recapitulates that of the endogenous flt-1 gene, because small and large vessels are labeled by eGFP during embryonic development; after birth, the expression becomes more restricted to small vessels. We have explored this in the cardiovascular system more in detail and found that all small vessels and capillaries within the heart are strongly eGFP?. In addition, myocardial injuries have been induced in transgenic mice and prominent vascular remodeling, and an increase in endothelial cell area within the peri-infarct area could be observed underscoring the utility of this mouse model. Thus, the transgenic flt-1/eGFP models are powerful tools to investigate and quantify vascularization in vivo and to probe the effect of different compounds on vessel formation in vitro.
Introduction
Vascular endothelial growth factor (VEGF) is a key molecule for vasculo-and angiogenesis, and is predominantly expressed in tissues with developing capillary networks [2] ; at the adult stage, VEGF has been found to be increased upon hypoxia [19, 32] . VEGF is a homodimeric glycoprotein and acts mainly via two receptors, VEGF receptor 1 (VEGFR-1 or Fms like tyrosine kinase, flt-1) and VEGF receptor 2 (VEGFR-2, fetal liver kinase, flk-1). While flk-1 has been identified as the receptor inducing a strong tyrosine kinase activity leading to endothelial cell proliferation, migration and enhanced vascular permeability [1, 22] , the role of flt-1 has remained more elusive. Flt-1 knockout mice die at E8.5-9.0 due to vascular overgrowth and uncontrolled vascularization [5] indicating that flt-1 plays a critical role as a negative regulator during embryonic development. Similarly, abnormal angiogenesis in the adult has also been linked to flt-1 receptor function and has been proposed to underlie several diseases such as rheumatoid arthritis, atherosclerosis or diabetes [8, 16] ; this is also true for tumor and metastasis formation where flt-1 is suspected to play a role [6, 10] .
Because of the expression of flt-1 in ischemic tissues undergoing re-vascularization [15, 39] and its involvement in various pathological states, we reasoned that transgenic in vitro and in vivo models using the flt-1 promoter would be very interesting. Herein we report the generation of stable, transgenic ES cells and mice in which eGFP expression is driven by the flt-1 promoter. Our data reveal persistent flt-1/eGFP expression in small vessels in the in vitro and in vivo systems. In addition, we also demonstrate the utility of the transgenic mouse model to investigate and quantitate vascularization in the heart after myocardial infarction. This may also prove helpful for the analysis of different signaling pathways in response to cardiac injury [12, 23, 38] .
Materials and methods

Generation of flt-1/eGFP vector
For the generation of the flt-1/eGFP vector, the 2.2 kb flt-1 promoter [26] was amplified from murine genomic DNA (Promega, Mannheim, Germany) using a nested polymerase chain reaction (PCR) strategy. In the first step, a larger fragment (2.3 kb) containing the flt-1 promoter was amplified (fw: 5 0 GGA GAA ACT ATC GAA GGC CAC AGC 3 0 , rev: 5 0 GTC CCC TCC TGC TTC TGC T 3 0 ). This product was applied as template to amplify the 2.2 kb flt-1 promoter using the primers previously reported by Quinn et al. [26] (fw: 5 0 GTC AAA TAC CTG TCT GGC TTC 3 0 , rev: 5 0 GTC CCC TCC TGC TTC TGC T 3 0 ). A third PCR step was carried out using the modified second primer pair in order to introduce restriction sites for EcoRI (fw: 5 0 TTC GGA ATT CGT CAA ATA CCT GTC TGG CTT C 3 0 ) and SalI (rev: 5 0 ATA TGT CGA CGT CCC CTC CTG CTT CTG CT 3 0 ). Finally, the fragment was digested with EcoRI and SalI to obtain sticky ends, and the flt-1 promoter was inserted into the multiple cloning site of the pEGFP-1 plasmid (Clontech Lab. Inc., Saint-Germain-en-Laye, France) via ligation. The flt-1/eGFP vector was applied for electroporation of D3 and G4 ES cells.
Generation of the flt-1/eGFP BAC vector BAC clones covering the promoter region of the flt-1 gene (RP24 225B5: 187,203 bps and RP23 300K18: 238,695 bps) were obtained from the Children's Hospital Oakland Research Institute (CHORI); BAC DNA was transferred into SW105 E. coli cells by electroporation (can be obtained from NCI-Frederick website http://recombineering.ncifcrf.gov/). An eGFP-pA cDNA was designed to be inserted at the initiation codon in the first exon of the flt-1 gene within the BACs. Therefore, homologous arms were generated by PCR using the pEGFP-1 vector as template. For this end, the following primers were applied: fw: 5 0 CGG CCT CGG   AGA GCG CGG GCA CCG GGC CAA CAG GCC GCG  TCT TGC TCA CCT GGC CAC AAC CAT GGT GAG 3  0 ,  rev: 5  0 TGA GAA GCA GAC ACC CGA GCA GCG CGT  AAG GCA AGA CCG CGG TGT CCC AGC CCG CGT  TTA TGA ACA AAC GAC 3 0 . Electrocompetent SW105 E. coli cells containing the BACs were electroporated with the targeting cassette, and clones with successful recombination were selected with kanamycin and chloramphenicol. Homologous recombination was verified by PCR with primers spanning the homology region. Then the flt-1/eGFP BAC was used for electroporation in G4 ES cells.
Generation of transgenic ES cell clones (flt-1/eGFP and flt-1/eGFP BAC ES cells)
To generate transgenic ES cell clones, 5 9 10 6 D3 or G4 ES cells were electroporated with 40 lg of the linearized flt-1/eGFP vector or the circular flt-1/eGFP BAC in PBS with one pulse at 250 V and 500 lF (Bio-Rad Gene Pulser, Munich, Germany) and plated on 10 cm cell culture dishes with feeder cells. After selection with G418 (300 lg/ml for D3 and 165 lg/ml for G4, Invitrogen, Karlsruhe, Germany), resistant colonies were picked and propagated for differentiation.
Cultivation and differentiation of transgenic ES cell clones
Undifferentiated ES cells of the D3 line (ATCC, Wesel, Germany) were cultured on a feeder layer in Dulbecco's modified Eagle medium (DMEM), supplemented with 15% fetal calf serum (FCS), 0.1 mM nonessential amino acids, 50 lg/ml penicillin and streptomycin solution (all from Invitrogen, Karlsruhe, Germany), 0.1 mM b-mercaptoethanol (Sigma Aldrich, Steinheim, Germany), 500 U/ml leukemia inhibitory factor (LIF, Chemicon, Hofheim, Germany) and G418.
ES cells of the G4 line [7] were cultured in Knockout DMEM (Invitrogen, Karlsruhe, Germany) plus the additives mentioned above (G418 165 lg/ml) and 2.0 mM L-glutamine (Invitrogen, Karlsruhe, Germany).
ES cell differentiation was performed using embryoid body (EB) formation via mass culture [11] or hanging drop method [36] . For differentiation, cells were cultivated in Iscove's MEM high-glucose medium (Invitrogen, Karlsruhe, Germany) supplemented with 20% FCS plus additives in the absence of LIF.
After 5 days of differentiation, transgenic EBs were plated on cover slips coated with 0.1% gelatine solution (Sigma Aldrich, Steinheim, Germany). Then, eGFP expression was evaluated on a daily basis. To examine the re-formation of vascular structures, day 5 EBs were digested by collagenase B (Roche, Mannheim, Germany) and single cells were plated on a Petri dish coated with 0.1% gelatine.
RT-PCR
For RT-PCR, RNA of flt-1/eGFP EBs at differentiation days 0, 3, 6, 9, 12 and 21 were isolated by the acid guanidine thiocyanate-phenol-bromo-chloro-propane (BCP) extraction method. The integrity of RNA extracts was assessed on a 1% MOPS gel and RNA was visualized by ethidium bromide staining. The amount of total RNA was determined by a NanoDrop spectrometer (Peqlab).
First [21] . Chimeric mice could be identified by coat color and were bred with CD1 mice to examine germline transmission. Offspring was tested for transgene integration by PCR of the tail tips with the following primer pair: fw: 5 0 TTC TTC TGA GCG GGA CTC TG 3 0 , rev: 5 0 GTC TAA GCG GTG ATG CCA AC 3 0 .
Time lapse microscopy of vessel development in ES cell clones
Flt-1/eGFP BAC EBs were plated on culture dishes with glass bottom (Greiner bio GmbH) and cultivated until day 5 ? 5. Time lapse microscopy was performed in a temperature (37°C) and CO 2 (5%) controlled chamber with a fluorescent microscope (Axiovert 200 M, Carl Zeiss MicroImaging, Inc.) using the Colibri system (blue LED), a GFP-filter and a 209 objective. Pictures and movies were generated with the Axiovision Rel. 4.8 software (Zeiss). EBs were monitored up to 48 h and pictures taken every 15 min.
Teratoma assay
For teratoma assays, single transgenic flt-1/eGFP ES cells of the D3 line were obtained by trypsin dissociation (Invitrogen, Karlsruhe, Germany). One million cells were injected subcutaneously into the left and right hindlimb of Fox Chase SCID Ò Beige Mice (Charles River, Sulzfeld, Germany). Tumors were harvested on day 21 after injection; cryosections were generated and immunohistochemistry (see below) or staining with the hematoxylin and eosin (H&E) method was performed. Pictures of H&E stainings were taken on a Zeiss Axiostar plus equipped with an Axiocam MRc 5 camera.
Immunohistochemistry of EBs, teratomas, embryos and organs
Pictures of E9.5 and E14.5 embryos as well as of whole organs were taken with a Leica MZ 16F stereomicroscope. Tissues were fixated with 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS). Thereafter, teratomas, embryos and organs were transferred to 20% sucrose, cryopreserved and then cryosections were generated. For immunohistochemistry, tissues were permeabilized and stained with primary antibodies against VEGF receptor 2 [VEGFR-2, flk-1, (1:100)], PECAM (1:800, both BD Biosciences, Heidelberg, Germany), VE-Cadherin (1:100, CD144, eBiosience, Frankfurt, Germany), CD45 (Ab-6, 1:800, Chemicon), vimentin (1:1,000, Chemicon) or Oct3/4 (1:100, Santa Cruz). As secondary antibodies, Cy3 or Cy5 anti-rat, anti-mouse or anti-chicken (1:400, Dianova, Hamburg, Germany) were applied. Nuclear staining was performed with Hoechst 33342 (BD, Heidelberg, Germany).
Pictures of stained specimen were taken with an inverted fluorescence microscope Axio Imager with ApoTome optical sectioning module (Zeiss, Jena, Germany).
Myocardial infarction of flt-1/eGFP BAC mice Myocardial infarctions were generated in 10-week-old flt-1/eGFP BAC mice by cryoinjury (n = 3) or left coronary artery (LCA) ligation (n = 6) as described previously [11, 28] . Mice were killed 3 or 6 days after injury to determine eGFP? vessels in the infarcted hearts. For quantitation of endothelial cell area after cryoinfarction, 3 transversal sections per heart at a distance of 100 lm each were analyzed. Microscopic pictures of the sections were acquired with the MosaiX function of the Axiovision software (Zeiss). Then, three regions in each section were defined: native heart tissue was identified based on the autofluorescence of cardiomyocytes, the peri-infarct zone comprised the lesioned and vascularized area without cardiomyocytes, and in the infarct zone only a few single nuclei were found. The eGFP? area within these regions was measured and normalized to the total area of the respective region.
Statistical analysis
Data are expressed as mean ± SEM. Statistical significance was determined by Student's unpaired t test. P \ 0.05 was considered statistically significant.
Results
Generation of flt-1/eGFP embryonic stem (ES) cells
To generate flt-1/eGFP ES cells, we first used the 2.2 kb flt-1 promoter element [26] that was isolated from mouse DNA by a nested PCR strategy and cloned into an eGFP plasmid. The vector was used for electroporation of murine ES cells of the D3 and G4 line. Screening revealed that only one out of 18 (D3) and one out of 76 (G4) clones showed eGFP expression restricted to vascular networks. These clones displayed only weak eGFP expression in the undifferentiated state (day 0, Fig. 1a) as has been reported for other endothelial markers such as PECAM [27] or flk-1 [9] . During mesodermal differentiation in the EB system at early stages, we could detect eGFP? clusters, later bright eGFP? elongated branches (Fig. 1b-d, arrows) developed giving origin to extensive eGFP? networks that can be best seen after plating (Fig. 1d-f, arrow heads) . Immunohistochemistry of EBs revealed that flt-1/eGFP and the endothelial specific marker flk-1 were to some degree differentially expressed in cell clusters of very early differentiation stage EBs, whereas there was almost a complete overlap between eGFP expression (green) and staining for the endothelial cell markers flk-1 (red, Fig. 1g , h, j) and PECAM (red, Fig. 1k , l, n) in endothelial tubes at later stages. We determined the endothelial specificity of the flt-1-driven eGFP expression more in detail by analyzing the overlap between eGFP fluorescence and PECAM immunostaining at the single cell level (approximately 1,000 cells) upon dissociation of EBs 5 days after plating (day 5 ? 5 EBs). We found that 92.7% of the cells were eGFP? PECAM?, 6.4% eGFP-PECAM? and only 0.9% eGFP? PECAM-. Thus, on day 10 of differentiation, almost all PECAM? cells showed eGFP fluorescence, while only very few cells were eGFP? but PECAM-. We tried to further characterize the cell biological identity of this subtype and found that some of these eGFP? PE-CAM-cells displayed weak Oct3/4 staining (data not shown) suggesting that these were, as reported earlier [18] , undifferentiated flt-1 expressing ES cells; other cells were stained by an antibody against vimentin, indicating mesodermal identity. We next explored the eGFP labeling in newly forming vessels; for this purpose, day 5 EBs were dissociated into single cells. Within 3 days after re-plating, sprouting of eGFP? cells appeared and within 7 days even prominent vascular network formation could be detected (Suppl. Fig. 1a-d) . The kinetics of flt-1 and eGFP expression was also evaluated by PCR and revealed that flt-1 mRNA expression was very low until day 3 of differentiation and peaked on day 9, similar as the eGFP mRNA expression (Fig. 1o) . These kinetics were corroborated by Western blot analysis of eGFP protein expression; here, peak levels were measured on day 12 (Fig. 1p) . Thus, the 2.2 kb flt-1 promoter element driving eGFP generated an endothelial-specific expression pattern in differentiating ES cells with a peak expression around days 9-12. However, with the 2.2 kb flt-1 promoter element, only very few 300 lm (a-f), 200 lm (g, k) , 100 lm (h-j, l-n). o Time course of flt-1 and eGFP mRNA expression levels revealed peak signals on day 9. p Time course of eGFP protein expression yielded peak levels on day 12 c transgenic ES cell clones with endothelial-specific eGFP labeling could be obtained.
Flt-1/eGFP ES cells can generate eGFP? vessels in vivo
Next, we wanted to explore whether the flt-1/eGFP ES cells could yield vascular structures in vivo, and to this end flt-1/ eGFP ES cells were injected subcutaneously into severely combined immune-deficient (SCID) mice. 3 weeks after injection, teratoma-like tumor masses had formed (Fig. 2a, b) , which displayed prominent eGFP fluorescence signals under the stereomicroscope (Fig. 2c) . Teratoma formation was confirmed by histological analysis, because derivatives of all three germ layers such as columnar epithelium (endoderm, Fig. 2d, arrow) , muscle (mesoderm, Fig. 2e , arrow) and squamous epithelium (ectoderm, Fig. 2f, arrow) could be found. Fluorescence microscopy of cryosections revealed high numbers of eGFP? cells (Fig. 2h, i, l, m) ; their endothelial nature was confirmed by immunostainings for flk-1 (Fig. 2g, i) and PECAM (Fig. 2k, m) . We further investigated eGFP? vascular structures using bright field In the teratomas tissue types of the three germ layers were found: columnar epithelium (endoderm, arrow, d), muscle cells (mesoderm, arrow, e) and squamous epithelium (ectoderm, arrow, f). Sections revealed overlap between eGFP (green, h, i, l, m) with flk-1 (red, g, i) and PECAM (red, k, m) immunostainings. Bright field pictures showed that vascular structures contained erythrocytes (insets) in their lumina (j, n), blue = Hoechst, bars 500 lm (a-c), 200 lm (d-f), 100 lm (g-n), 25 lm (insets) microscopy (Fig. 2j, n) and found that these were likely functional blood vessels due to their content of red blood cells (Fig. 2j, n, insets) . These experiments show that flt-1/ eGFP ES cells can build up vessels in vivo.
Because of the endothelial-specific eGFP expression in vitro and in vivo, we wanted to generate a transgenic mouse model in order to enable the identification of blood vessels in different organs in vivo. One possibility is the diploid or tetraploid aggregation of ES cells with wild-type mouse embryos which yields a mouse with an identical genetic background as in the in vitro system. However, when performing karyotyping of the two ES cell clones, we found a high percentage of cells with chromosomal aberrations in both cases. In fact, aggregation of those transgenic ES cells with diploid morula stage CD1 embryos only produced two animals with a high degree of chimerism but no germ-line transmission. We also tested direct generation of transgenic mice by pronuclear injection of the construct, but the 33 transgenic animals obtained by this method displayed unspecific expression outside the vascular system (data not shown).
Generation of flt-1/eGFP BAC ES cells
As the 2.2 kb flt-1 promoter element produced only two clones with endothelial-specific reporter gene expression and no transgenic mice with the expected expression pattern, we suspected that the promoter may be subject to negative position effects or that critical regulatory elements of the flt-1 promoter may be missing. We, therefore, chose the bacterial artificial chromosome (BAC) technology for the generation of new transgenic ES cell lines. EGFP-pA cDNA was inserted into the first exon of two different BACs spanning the murine flt-1 promoter region by homologous recombination (Fig. 3a) . The resulting flt-1/ eGFP BAC constructs were used for electroporation of G4 ES cells [7] . G418 selection provided nine clones and four of these displayed a uniform expression pattern with obvious endothelial-specific eGFP labeling during differentiation. The time-course of eGFP expression and network formation proved to be very similar to the above-described flt-1/eGFP clones with weak eGFP expression at the undifferentiated stage, first vascular structures around day 7 and a peak of vascular network formation around day 12 of differentiation. The vascular networks covered large areas of the EBs and were clearly visible up to late stages of differentiation (day 5 ? 13, Fig. 3b) ; their formation via sprouting angiogenesis could be monitored with time lapse microscopy (Suppl. Video 1). In analogy to the flt-1/eGFP clones, immunohistochemistry revealed almost a complete overlap of the eGFP expression with staining for flk-1 (Fig. 3c-e) , PECAM (Fig. 3f-h ) and also VE-Cadherin (Fig. 3i-k) on day 5 ? 6. These experimental results demonstrated that transfection of ES cells with the flt-1/ eGFP BAC construct provides clones with endothelialspecific eGFP expression at a very high frequency.
Generation of flt-1/eGFP BAC transgenic mice
For the generation of transgenic mice, flt-1/eGFP BAC ES cell clones were karyotyped and diploid aggregation with CD1 embryos was performed. Eight chimeric mice with a high degree of coat color chimerism were obtained. Seven of them provided germ-line transmission when bred with CD1 mice. Flt-1/eGFP BAC mice were viable and fertile and no obvious adverse side effects of the flt1/eGFP expression on development and growth were noted.
Main focus of our analysis of the mice was the expression pattern in the cardiovascular system due to our scientific interest in its development and diseased state. First, we investigated the eGFP expression under fluorescence light at an early (E9.5) and a later (E14.5) embryonic developmental stage. Flt-1/eGFP BAC embryos at E9.5 were transparent and displayed bright eGFP expression in large and small vessels (Fig. 4a-c) . PECAM-stained slices evidenced a very good overlap with eGFP fluorescence (Fig. 4d) ; especially, the endocardium of the heart and the outflow tract were strongly labeled by eGFP (Fig. 4e, f) . At E14.5, an almost homogeneous fluorescence was observed caused by the vascularized skin (Fig. 4g) . The strong eGFP labeling of large and small vessels was also seen at this stage (Fig. 4h) . In the heart, in particular, the valves were highly fluorescent (Fig. 4i, j) . Next, we characterized the mice at the adult stage; the transgenic mice could be identified by their eGFP fluorescence in the ears using a trans-illumination approach. When whole organs were analyzed with a stereomicroscope, the eGFP fluorescence was found in vascular structures of all organs except the liver, namely the eye (Fig. 5a ), the brain (Fig. 5b ) and the skin (Fig. 5c) . Immunohistochemistry of cryosections with PECAM antibody (red) evidenced that the native eGFP (green) expression was restricted to the vascular endothelium in the organs analyzed, such as the intestinal villi of the gut (Fig. 5d-f ), the lung (Fig. 5g-i) , the thymus (Suppl. Fig. 2a-c ) and the kidney (Suppl. Fig. 2d-f ) with vasa recta and glomeruli (inset). Within the heart, we investigated the eGFP expression in detail and found that all small vessels with a diameter below 50 lm displayed strong eGFP expression and a complete overlap with PECAM staining, while larger vessels were eGFP- (Fig. 5j-l,  inset) . EGFP expression was endothelial-specific as smooth muscle cells and cardiomyocytes were eGFP- (Fig. 5j-l) . Interestingly, the endothelium in large arteries such as aorta (Suppl. Fig. 3a-c) or carotid artery (Suppl. Fig. 3d-f ) was entirely eGFP-, whereas that of larger veins such as the jugular vein was strongly labeled (Suppl. Fig. 3g-i) . Thus, the flt-1/eGFP BAC mouse line is a valid tool to determine flt-1 expression during development and to visualize small vessels in a variety of different organs at the adult stage; prominent eGFP expression was found in all endothelial cells of small vessels in the adult heart.
Vascularization of myocardial infarction in flt-1/eGFP BAC mice Because of the excellent eGFP labeling of small vessels in the flt-1/eGFP BAC mice, we hypothesized that this model enables characterization and quantitation of the vascularization in organs post-injury. After myocardial infarction, the vascularization of the infarct and peri-infarct areas are critical determinants of survival and remodeling in the heart; we, therefore, assessed the utility of our flt-1/ eGFP BAC transgenic mouse in infarct models. This type of analysis is currently strongly limited using standard immunohistochemistry due to problems with antibody staining or strong background signals in the infarct regions. We induced cryoinjury or left coronary artery ligation and investigated the ensuing re-vascularization. The cryoinjury has the distinct advantage of reproducible lesions, uniform tissue necrosis of the injured area within the first 3 days and fibrotic repair in the following few days [29] . 3 and 6 days after the procedure, the lesion site could be easily identified in flt-1/eGFP BAC mice using macroscopic bright field and fluorescence pictures (Fig. 6a-d) . On day 3 after cryoinfarction there were, as expected, almost no intact cells and no eGFP fluorescence found in the center of the lesion (Fig. 6e) . In contrast, in the peri-infarct area, a high number of eGFP? round-shaped structures displaying distinct lumen formation could be detected (Fig. 6f) , whereas native cardiomyocytes and capillaries without obvious lumina were found in the non-infarcted border zone (Fig. 6g) . The vascular eGFP? structures in the periinfarct zone (Fig. 6h) were clearly endothelial cells due to positive PECAM staining (Fig. 6i, j) and negative staining were highly transparent; large and small vessels proved strongly eGFP?; distinct eGFP? vessels could be found at the head (b) and in the intersomitic region (c), the dotted squares define the regions of the embryo with magnifications in b and c. d In sections of E9.5 embryos a high overlap of eGFP (green) with PECAM staining (red) was observed. e, f In the heart of E9.5 embryos strong eGFP (green) and PECAM (red) expression was seen in the endocardium of the cavities and the outflow tract. g At E14.5 eGFP? vessels in the skin produced a bright eGFP signal throughout the body. h Sections of E14.5 embryos showed flt-1/eGFP (green) expression in large and small arteries (PECAM = red). i, j At this stage the heart valves displayed a very strong eGFP (green) signal (RA right atrium, RV right ventricle, PV pulmonary valve, AV aortic valve, TV tricuspidal valve, PECAM = red). Note that the dotted grey lines label the surface of the embryo (d, h) and the dotted white lines define the embryonic heart (d-f, h-j). Bars 1,000 lm (a, g), 125 lm (b, c), 500 lm (d, h), 250 lm (e, f), 200 mm (i, j) against the pan-hematopoietic marker CD45 (Suppl .  Fig. 4) ; interestingly, at this stage, the PECAM staining was relatively weak. On day 6 after cryoinfarction, a few small vessels could be found in the central part of the lesion, most probably because of re-vascularization (Fig. 6k, arrow) . The eGFP? endothelial cells in the periinfarct zone had formed into more straight and elongated structures indicating pronounced vascular remodeling (Fig. 6l) , whereas the vascular structures in the noninfarcted regions remained unaltered (Fig. 6m) . The vascular structures in the peri-infarct zone at this stage displayed stronger eGFP and PECAM expression compared to Fig. 6n-p) , possibly indicating a more mature stage. When the relative area of eGFP? cells in the peri-infarct zone was measured, we found a strong increase after 6 days (0.027 ± 0.001, n = 6) compared to 3 days (0.016 ± 0.001, n = 3); in contrast, there was no detectable change in the endothelial area of the native myocardium (Fig. 6q) . We also applied left coronary artery (LCA) ligations in the flt-1/eGFP BAC mouse which is a more physiological injury model; the infarct areas were less regular and well-defined compared to cryoinjuries and therefore quantitation of re-vascularization was not performed. At 3 days after the occlusion, there were infarct zones with almost no eGFP? vascular structures (Fig. 6r) , but in the peri-infarct areas small sinuous eGFP? vessels were detected (Fig. 6s) . At 6 days after occlusion, eGFP? structures were found within the infarct (Fig. 6u) , whereas eGFP? elongated vessels were visible in the peri-infarct zone, some of these with lumen formation (Fig. 6v, arrow) . The heart structure in the non-infarcted areas was, as expected, unperturbed (Fig. 6t, w) . Thus, the overall morphological characteristics of the vascular remodeling proved very similar in both myocardial lesion models.
Our data demonstrate that the flt-1/eGFP BAC mouse allows direct visualization of small vessels in the heart, and therefore facilitates the analysis of vascularization upon different types of myocardial injury.
Discussion
Aim of the present study was to generate novel transgenic in vitro and in vivo models in which small vessels are labeled by a fluorescent reporter molecule. We have chosen the flt-1 promoter because it has been proposed as a bona fide marker of endothelial cells in general and, in particular, of small vessels. Furthermore, this promoter has also attracted our attention due to its reported up-regulation and involvement in re-vasularization of the ischemic heart [13, 15] . However, to date, the flt-1 expression pattern could be only characterized with molecular approaches and with the help of a lacZ knock in mouse model due to the lack of specific antibodies. Our experimental data prove that the flt-1 driven eGFP expression is endothelial cell-specific in the vasculature, strongly labels small vessels in various organs and provides an excellent approach to monitor vascularization during development and disease.
We found that BAC constructs strongly increased the efficiency of generating transgenic ES cell lines with an endothelial-specific expression pattern compared to the use of shorter promoter segments. This points to the relevance of negative position effects or additional regulatory sequences outside of the 2.2 kb flt-1 promoter element that most likely determine tissue specificity. We noticed weak flt-1 mRNA expression in undifferentiated flt-1/eGFP ES cell lines which is in line with other studies, where low mRNA levels of the VEGF receptors flt-1 [18] and flk-1 [9] were reported in undifferentiated ES cells. Even though flt-1 and eGFP mRNA expression were both driven by the flt-1 promoter, we found high eGFP mRNA and protein levels at this stage. Because this is the case for the 2.2 kb promoter element as well as for the BAC, it is unlikely due to the lack of regulatory sequences, but suggests that either eGFP mRNA processing is more efficient or eGFP mRNA is more stable compared to flt-1 mRNA [30] .
During ES cell differentiation and starting from relatively early embryonic developmental stages in mouse, endothelial-specific eGFP expression in the vasculature was detected. In fact, in the transgenic mouse eGFP? vessels were found at all developmental stages from the embryo to the adult. However, obvious differences in the expression pattern were noticed. At the embryonic stage both large and small vessels were eGFP?; furthermore, the cardiac valves were strongly positive which fits to the reported relevance of flt-1 as a regulator of VEGF signals for endothelial to mesenchymal transition in the outflow tract [31] or in the atrioventricular canal [4] during heart valve formation. Overall, the embryonic expression pattern of flt-1/eGFP overlapped with earlier studies using in situ hybridization or lacZ staining [2, 5] . While flt-1 expression was thought to primarily label developing endothelium, our experimental data demonstrate that it is strongly expressed in all small vessels also at the adult stage. This finding supports the assumption that flt-1 also labels quiescent endothelium [25, 35] . In contrast to the embryo, there was no eGFP signal in large arteries, whereas the endothelium of large veins was labeled. Small arteries are thought to play a critical role for vascular remodeling and re-vascularization in response to intermittent or permanent ischemia in the heart and we therefore probed this hypothesis by inducing different types of cardiac lesions in our transgenic mice. We found large clusters of eGFP? endothelial cells in the peri-infarct area on day 3 post-lesion. The elongation of these structures between day 3 and 6 as well as the concomitant increase of eGFP and PECAM expression could be indicative for the maturation of these vascular structures. In addition, in the center of the lesion no eGFP? vessels were visible on day 3 after cryoinjury. Between day 3 and 6, small vascular structures were found to emerge indicating re-vascularization. Similar morphological changes were also found when analyzing re-vascularization at different time points after LCA ligation.
Thus, the endothelial cell-specific eGFP labeling in ES cells and transgenic mice enables to visualize vascularization in early developmental stages and upon injury; moreover by these transgenic models, the screening of drugs and compounds for embryotoxic effects and/or their modulation of vascular structures in vitro and in vivo is possible [3, 14, 20, 24] . In addition, eGFP? endothelial cells can be highly enriched by fluorescence-activated cell sorting and this allows to determine their molecular and cell biological characteristics as well as their regenerative potential [37] . The experimental data using cardiac injury models suggest that this transgenic mouse model will also be very helpful to further explore mechanisms underlying vascular remodeling and re-vascularization.
